X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs GLENMARK PHARMA - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE GLENMARK PHARMA CADILA HEALTHCARE/
GLENMARK PHARMA
 
P/E (TTM) x 32.6 11.9 273.1% View Chart
P/BV x 6.1 3.1 192.2% View Chart
Dividend Yield % 0.8 0.4 202.8%  

Financials

 CADILA HEALTHCARE   GLENMARK PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-17
GLENMARK PHARMA
Mar-17
CADILA HEALTHCARE/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs460993 46.3%   
Low Rs305729 41.8%   
Sales per share (Unadj.) Rs92.1325.5 28.3%  
Earnings per share (Unadj.) Rs14.839.3 37.7%  
Cash flow per share (Unadj.) Rs18.548.7 38.0%  
Dividends per share (Unadj.) Rs3.202.00 160.0%  
Dividend yield (eoy) %0.80.2 360.2%  
Book value per share (Unadj.) Rs68.0159.2 42.7%  
Shares outstanding (eoy) m1,023.74282.17 362.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.22.6 157.0%   
Avg P/E ratio x25.821.9 117.8%  
P/CF ratio (eoy) x20.717.7 117.0%  
Price / Book Value ratio x5.65.4 104.0%  
Dividend payout %21.65.1 424.3%   
Avg Mkt Cap Rs m391,581242,991 161.2%   
No. of employees `00016.913.0 130.0%   
Total wages/salary Rs m15,00216,408 91.4%   
Avg. sales/employee Rs Th5,594.57,083.9 79.0%   
Avg. wages/employee Rs Th890.11,265.4 70.3%   
Avg. net profit/employee Rs Th899.9855.1 105.2%   
INCOME DATA
Net Sales Rs m94,29591,857 102.7%  
Other income Rs m1,286374 344.2%   
Total revenues Rs m95,58192,230 103.6%   
Gross profit Rs m19,03620,367 93.5%  
Depreciation Rs m3,7502,644 141.8%   
Interest Rs m4502,373 19.0%   
Profit before tax Rs m16,12215,724 102.5%   
Minority Interest Rs m3380-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3-810 0.4%   
Tax Rs m1,2893,827 33.7%   
Profit after tax Rs m15,16811,088 136.8%  
Gross profit margin %20.222.2 91.0%  
Effective tax rate %8.024.3 32.9%   
Net profit margin %16.112.1 133.3%  
BALANCE SHEET DATA
Current assets Rs m60,22368,746 87.6%   
Current liabilities Rs m53,05827,027 196.3%   
Net working cap to sales %7.645.4 16.7%  
Current ratio x1.12.5 44.6%  
Inventory Days Days7085 82.1%  
Debtors Days Days8896 92.3%  
Net fixed assets Rs m72,98424,132 302.4%   
Share capital Rs m1,024282 362.9%   
"Free" reserves Rs m68,57644,643 153.6%   
Net worth Rs m69,60044,925 154.9%   
Long term debt Rs m24,68445,363 54.4%   
Total assets Rs m152,207117,639 129.4%  
Interest coverage x36.87.6 482.9%   
Debt to equity ratio x0.41.0 35.1%  
Sales to assets ratio x0.60.8 79.3%   
Return on assets %10.311.4 89.7%  
Return on equity %21.824.7 88.3%  
Return on capital %17.919.1 93.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m21,28056,152 37.9%   
Fx outflow Rs m10,8748,084 134.5%   
Net fx Rs m10,40648,068 21.6%   
CASH FLOW
From Operations Rs m13,4956,574 205.3%  
From Investments Rs m-29,103-7,124 408.5%  
From Financial Activity Rs m23,1585,432 426.4%  
Net Cashflow Rs m7,5561,992 379.2%  

Share Holding

Indian Promoters % 74.8 48.3 154.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 6.9 120.3%  
FIIs % 5.9 34.4 17.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 10.5 104.8%  
Shareholders   44,069 56,727 77.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   IPCA LABS  NOVARTIS  ALEMBIC PHARMA  MERCK LTD  SANOFI INDIA  

Compare CADILA HEALTHCARE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Down Around 1%; Telecom & Metal Stocks Decline(01:30 pm)

Indian share markets are trading in the red presently. Sectoral indices are trading in the red with stocks in the telecom sector and metal sector witnessing maximum selling pressure.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Feb 19, 2018 03:37 PM

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS